- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT07579871
Sleep and Stroke Rehabilitation Study (SnSRehabS)
The study aims to map sleep disorders and their impact on the ability to engage in an active daily life among people who have had a stroke, with particular focus on how sleep apnea can be identified.
The study has the following objectives:
- To examine the occurrence of sleep apnea, insomnia, excessive daytime sleepiness, and restless legs syndrome/periodic limb movements in patients with ischemic stroke three months after onset.
- To investigate associations between these sleep disorders and physical and mental health, fatigue, quality of life, cognitive and physical function, and daily physical behavior including physical activity levels.
- To identify which clinical factors and patient reported data, including patient reported data from commercial wearable health technology, predict a diagnosis of sleep apnea.
- To examine how sleep disorders affect changes in physical and mental health, fatigue, quality of life, cognitive and physical function, and daily physical behavior including physical activity levels one year after stroke.
Обзор исследования
Статус
Подробное описание
There is currently a lack of understanding regarding how common sleep disorders are after stroke and how extensive their impact is on physical and psychological conditions. This project will investigate how common sleep disorders are in connection with stroke and how they affect patients with stroke physically and psychologically, as well as their level of activity in everyday life.
The project will also examine how healthcare services could identify who should undergo an assessment for sleep apnea. Today, there are commercial health technology products that alert users to potential breathing problems during the night, but it is unclear whether the information a patient presents to their doctor, based on these commercial health technology products, should be included in the clinical assessment of sleep apnea risk.
The project will consecutively invite individuals with stroke from Skåne and Blekinge, Sweden. Three months after their stroke, participants will complete questionnaires, undergo actigraphy and wear a commercial health technology product in the form of a smartwatch for one week, as well as complete an overnight respiratory recording. Based on this, it will be possible to determine how many participants have a sleep disorder and how it has affected them, as well as which factors make it likely that an individual has sleep apnea.
Тип исследования
Регистрация (Оцененный)
Контакты и местонахождение
Контакты исследования
- Имя: Malin E. a. K. Gustafsson, M.D., Ph.D.
- Номер телефона: 0046451-29 60 00
- Электронная почта: malin_e.gustafsson@med.lu.se
Места учебы
-
-
Skåne County
-
Lund, Skåne County, Швеция
- Рекрутинг
- Skånes Universitetssjukhus, SUS
-
Контакт:
- Malin E. a. K. Gustafsson, M.D., Ph.D.
- Номер телефона: 004604617 10 00
- Электронная почта: malin_e.gustafsson@med.lu.se
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
- Взрослый
- Пожилой взрослый
Принимает здоровых добровольцев
Метод выборки
Исследуемая популяция
Описание
Inclusion Criteria:
- Ischemic stroke.
- First time stroke.
Exclusion Criteria:
- Short expected survival.
- Unable to carry HSAT equipment (e.g., gel nails; the patient is wearing other medical devices; motor or cognitive impairment without the possibility of assistance from healthcare staff or relatives).
- Reduced understanding of the project due to insufficient Swedish, which cannot be bridged with an interpreter.
Учебный план
Как устроено исследование?
Детали дизайна
Когорты и вмешательства
Группа / когорта |
|---|
|
Patients with ischemic stroke
Patients with first-time ischemic stroke in Skåne and Blekinge, Sweden.
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Occurrence of sleep apnea
Временное ограничение: Three months post-stroke.
|
Percent of participants with sleep apnea as assessed by Home Sleep Apnea Testing.
|
Three months post-stroke.
|
|
Occurrence of insomnia
Временное ограничение: Three months post-stroke.
|
Percent of participants with insomnia.
|
Three months post-stroke.
|
|
MoCA
Временное ограничение: Twelve months post-stroke.
|
MoCA (Montreal Cognitive Assessment) is a cognitive screening tool scored 0-30, where higher scores indicate better cognitive function; a score of 26 or above is considered normal, with an optional +1 point for individuals with ≤12 years of education.
|
Twelve months post-stroke.
|
|
MoCA
Временное ограничение: Three months post-stroke.
|
MoCA (Montreal Cognitive Assessment) is a cognitive screening tool scored 0-30, where higher scores indicate better cognitive function; a score of 26 or above is considered normal, with an optional +1 point for individuals with ≤12 years of education.
|
Three months post-stroke.
|
|
Occurrence of excessive daytime sleepiness
Временное ограничение: Three months post-stroke.
|
Percent of participants with excessive daytime sleepiness.
|
Three months post-stroke.
|
|
Physical movement behavior
Временное ограничение: One week of continuous accelerometer monitoring three months post-stroke.
|
Amount of time spent in different postures and activities during 24 hours.
|
One week of continuous accelerometer monitoring three months post-stroke.
|
|
Physical movement behavior
Временное ограничение: One week of continuous accelerometer monitoring twelve months post-stroke.
|
Amount of time spent in different postures and activities during 24 hours.
|
One week of continuous accelerometer monitoring twelve months post-stroke.
|
|
HADS
Временное ограничение: Three months post-stroke.
|
HADS (Hospital Anxiety and Depression Scale) includes two subscales (anxiety and depression) scored 0-21 each.
0 indicates no symptoms, and 21 indicates the most severe symptoms.
|
Three months post-stroke.
|
|
HADS
Временное ограничение: Twelve months post-stroke.
|
HADS (Hospital Anxiety and Depression Scale) includes two subscales (anxiety and depression) scored 0-21 each.
0 indicates no symptoms, and 21 indicates the most severe symptoms.
|
Twelve months post-stroke.
|
|
FAS
Временное ограничение: Three months post-stroke.
|
FAS (Fatigue Assessment Scale) is scored 10-50.
10 indicates no fatigue, and 50 indicates the most severe fatigue.
|
Three months post-stroke.
|
|
FAS
Временное ограничение: Twelve months post-stroke.
|
FAS (Fatigue Assessment Scale) is scored 10-50.
10 indicates no fatigue, and 50 indicates the most severe fatigue.
|
Twelve months post-stroke.
|
|
EQ-5D
Временное ограничение: Three months post-stroke.
|
EQ-5D produces an index score ranging from <0 to 1. 1 indicates full health, and lower values indicate worse health (with values below 0 representing health states considered worse than death). |
Three months post-stroke.
|
|
EQ-5D
Временное ограничение: Twelve months post-stroke.
|
EQ-5D produces an index score ranging from <0 to 1. 1 indicates full health, and lower values indicate worse health (with values below 0 representing health states considered worse than death). |
Twelve months post-stroke.
|
|
Level of breathing difficulties
Временное ограничение: Three months post-stroke.
|
Patient-reported breathing difficulties based on information they obtained from their commercial digital health smartwatch.
|
Three months post-stroke.
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Hba1c
Временное ограничение: Baseline.
|
HbA1c (Hemoglobin A1c) mmol/mol.
Represents the average amount of blood sugar attached to hemoglobin over the past two to three months
|
Baseline.
|
|
Cholesterol
Временное ограничение: Baseline.
|
Serum cholesterol in mmol/L
|
Baseline.
|
|
Creatinine
Временное ограничение: Basline.
|
Serum creatinine in µmol/L.
|
Basline.
|
Соавторы и исследователи
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
- Цереброваскулярные расстройства
- Заболевания головного мозга
- Заболевания центральной нервной системы
- Заболевания нервной системы
- Сосудистые заболевания
- Сердечно-сосудистые заболевания
- Психические расстройства
- Заболевания дыхательных путей
- Нарушения дыхания
- Расстройства сна и бодрствования
- Апноэ
- Расстройства сна, внутренние
- Диссомнии
- Инсульт
- Синдромы апноэ во сне
- Апноэ сна, обструктивное
- Нарушения засыпания и поддержания сна
- Расстройства чрезмерной сонливости
Другие идентификационные номера исследования
- 2025-03643-01
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
Сроки обмена IPD
Критерии совместного доступа к IPD
Qualified researchers affiliated with academic, clinical, or research institutions may request de-identified individual participant data underlying the results reported in the published article.
Researchers may submit a reasonable request to the Principal Investigator, including a description of the proposed analysis and data protection measures. Data access will be granted upon approval of the request and completion of a data-sharing agreement.
Совместное использование IPD Поддерживающий тип информации
- STUDY_PROTOCOL
- САП
- МКФ
- АНАЛИТИЧЕСКИЙ_КОД
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .